Molecular therapy : the journal of the American Society of Gene Therapy · 2026
Lactate-induced miR-7-5p/TRIM33 reprograms metabolic flux to suppress tumor growth and viral reactivation.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Xu Yifei, Min Xuehua, Zhang Zihan, Zhang Yulin, Chen Xiaoting, Wang Xinyu, Zhu Caixia, Robertson Erle, Zhang Qunling, Tong Yin, Zhang Liming, Wang Yuyan, Cai Qiliang
Аннотация
Cancer metabolic reprogramming generates a hostile tumor microenvironment (TME) characterized by lactate-driven acidosis, fostering tumor progression. Epstein-Barr virus (EBV), an oncogenic herpesvirus linked to multiple malignancies, thrives under such stress, yet how it interacts with and contributes to an acidic TME remains poorly understood. Here, we identify miR-7-5p as a lactate-downregulated microRNA with diagnostic potential in plasma from patients with EBV-associated diffuse large B cell lymphoma and nasopharyngeal carcinoma. TRIM33, a previously uncharacterized lactate-inducible transcriptional regulator of glycolytic flux, is directly targeted by miR-7-5p. Integrative multi-omics analyses reveal that lactate promotes TRIM33 binding to specific motifs in the promoters of key glycolytic genes, including SLC16A1, which enhances their expression and reprograms metabolism. Importantly, the loss of TRIM33 accelerates tumor growth, enhances EBV reactivation, and confers resistance to lactate-transporter inhibitors. Our finding provides circulating miR-7-5p as a noninvasive biomarker and reveals TRIM33 as an integrator of lactate stress, metabolism, and viral oncogenesis, offering a novel dual-targeting therapeutic strategy.